Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(55.6%)
Phase 2
3(33.3%)
Phase 3
1(11.1%)
9Total
Phase 1(5)
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06015659Phase 2Active Not Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Role: collaborator

NCT05128825Phase 2Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Role: lead

NCT07546500Phase 3Not Yet Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Role: lead

NCT04814108Phase 2Completed

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Role: lead

NCT04158336Phase 1Completed

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Role: lead

NCT04833582Phase 1Completed

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Role: lead

NCT05198804Phase 1Completed

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Role: lead

NCT05743036Phase 1Terminated

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Role: lead

NCT04516447Phase 1Recruiting

A Study of ZN-c3 in Patients With Ovarian Cancer

Role: lead

All 9 trials loaded